SEC Filing Summary: Frequency Therapeutics, Inc. (8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Frequency Therapeutics, Inc. (not Korro Bio, Inc.) on January 11, 2021. The registrant is a Delaware corporation with its principal executive offices in Woburn, MA, and its common stock trades on the Nasdaq Global Select Market under the symbol "FREQ". The company is classified as an emerging growth company.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report serves solely to disclose the availability of a corporate presentation and does not contain audited or unaudited financial statements.
Material Changes
No material changes to financial position or operations are reported in this document. The filing is procedural, intended to satisfy Regulation FD disclosure requirements regarding the posting of updated corporate materials.
Guidance, Outlook, and Management Commentary
On January 11, 2021, the Company posted an updated corporate slide presentation on its website under the "Investors & Media" section. A copy of this presentation is attached as Exhibit 99.1. The filing explicitly states that the information in the presentation is furnished, not filed, and is not subject to the liabilities of Section 18 of the Exchange Act. The Company undertakes no obligation to update, supplement, or amend the materials attached as Exhibit 99.1.
Investor Verification Checklist
- Verify the correct registrant name is Frequency Therapeutics, Inc., as the input metadata incorrectly referenced Korro Bio, Inc.
- Access the attached Exhibit 99.1 (Corporate Slide Presentation) directly from the SEC filing to review the actual business updates and outlook.
- Note that the slide presentation is not deemed "filed" for legal liability purposes under Section 18 of the Exchange Act.
- Confirm the company's status as an emerging growth company for potential differences in financial reporting standards.